Criteria for the selection of radionuclides for tumor radioimmunotherapy
The potential of utilizing monoclonal antibodies as carriers of radionuclides for the selective destruction of tumors (radioimmunotherapy, RIT) has stimulated much research activity. From dosimetric and other considerations, the choice of radiolabel is an important factor that needs to be optimized for maximum effectiveness of RIT. This paper reviews and assesses a number of present and future radionuclides that are particularly suitable for RIT based on the various physical, chemical, and biological considerations. Intermediate to high-energy beta emitters' (with and without gamma photons in their emission) are emphasized since they possess a number of advantages over alpha and Auger emitters. Factors relating to the production and availability of candidate radiometals as well as their stable chemical attachment to monoclonal antibodies are discussed. 34 refs., 4 tabs.
- Research Organization:
- Brookhaven National Lab., Upton, NY (United States)
- Sponsoring Organization:
- USDOE; USDOE, Washington, DC (United States)
- DOE Contract Number:
- AC02-76CH00016
- OSTI ID:
- 5332217
- Report Number(s):
- BNL-46589; CONF-9109287-1; ON: DE92000485
- Resource Relation:
- Conference: 4. international symposium on the synthesis and applications of isotopes and isotopically labeled compounds, Toronto (Canada), 3 Sep 1991
- Country of Publication:
- United States
- Language:
- English
Similar Records
Application of the linear-quadratic model to radioimmunotherapy: Further support for the advantage of longer-lived radionuclides
Application of the linear-quadratic model to radioimmunotherapy: Confirmation of the advantage of longer-lived radionuclides
Related Subjects
62 RADIOLOGY AND NUCLEAR MEDICINE
MONOCLONAL ANTIBODIES
LABELLING
RADIOIMMUNOTHERAPY
OPTIMIZATION
RADIOISOTOPES
COMPARATIVE EVALUATIONS
PRODUCTION
BETA DECAY RADIOISOTOPES
COPPER 67
GOLD 199
INDIUM 111
IODINE 131
ISOTOPE PRODUCTION REACTORS
LET
RADIOISOTOPE GENERATORS
RADIOPHARMACEUTICALS
RHENIUM 186
RHODIUM 105
SAMARIUM 153
SCANDIUM 47
TECHNETIUM 99
YTTRIUM 90
ANTIBODIES
BETA-MINUS DECAY RADIOISOTOPES
COPPER ISOTOPES
DAYS LIVING RADIOISOTOPES
DRUGS
ELECTRON CAPTURE RADIOISOTOPES
ENERGY TRANSFER
EVALUATION
EVEN-ODD NUCLEI
GOLD ISOTOPES
HEAVY NUCLEI
HOURS LIVING RADIOISOTOPES
IMMUNOLOGY
IMMUNOTHERAPY
INDIUM ISOTOPES
INTERMEDIATE MASS NUCLEI
INTERNAL CONVERSION RADIOISOTOPES
IODINE ISOTOPES
IRRADIATION REACTORS
ISOMERIC TRANSITION ISOTOPES
ISOTOPES
LABELLED COMPOUNDS
MEDICINE
MINUTES LIVING RADIOISOTOPES
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
ODD-ODD NUCLEI
RADIOIMMUNOLOGY
RADIOLOGY
RADIOTHERAPY
RARE EARTH ISOTOPES
RARE EARTH NUCLEI
REACTORS
RHENIUM ISOTOPES
RHODIUM ISOTOPES
SAMARIUM ISOTOPES
SCANDIUM ISOTOPES
SECONDS LIVING RADIOISO
TECHNETIUM ISOTOPES
THERAPY
YEARS LIVING RADIOI
YEARS LIVING RADIOISOTOPES
YTTRIUM ISOTOPES
400703* - Radiochemistry & Nuclear Chemistry- Radioisotope Production
550604 - Medicine- Unsealed Radionuclides in Therapy- (1980-)